Celyad Oncology SA (CYAD.BR)
EUR 0.47
(0.65%)
EUR 0.47
(0.65%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 8.49 Million EUR | -58.1% |
| 2022 | 20.26 Million EUR | -24.7% |
| 2021 | 26.9 Million EUR | 2.53% |
| 2020 | 26.24 Million EUR | -10.67% |
| 2019 | 29.37 Million EUR | -28.84% |
| 2018 | 41.28 Million EUR | 39.34% |
| 2017 | 29.62 Million EUR | -13.06% |
| 2016 | 34.07 Million EUR | 14.84% |
| 2015 | 29.67 Million EUR | 48.99% |
| 2014 | 19.91 Million EUR | 79.79% |
| 2013 | 11.07 Million EUR | 313.53% |
| 2012 | -5.18 Million EUR | -256.67% |
| 2011 | 3.31 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 3.08 Million EUR | 0.0% |
| 2023 FY | 11.48 Million EUR | -43.32% |
| 2023 Q4 | 4.74 Million EUR | 0.0% |
| 2023 Q2 | 5.42 Million EUR | 0.0% |
| 2022 FY | 20.26 Million EUR | -24.7% |
| 2022 Q4 | 12.01 Million EUR | 0.0% |
| 2022 Q2 | 7.64 Million EUR | 2.04% |
| 2022 Q1 | 7.49 Million EUR | -4.0% |
| 2021 Q2 | 6.36 Million EUR | -2.96% |
| 2021 Q4 | 7.8 Million EUR | 26.13% |
| 2021 FY | 26.9 Million EUR | 2.53% |
| 2021 Q1 | 6.55 Million EUR | 1.2% |
| 2021 Q3 | 6.18 Million EUR | -2.72% |
| 2020 FY | 26.24 Million EUR | -10.67% |
| 2020 Q3 | 5.75 Million EUR | -62.24% |
| 2020 Q4 | 6.47 Million EUR | 12.51% |
| 2020 Q2 | 15.24 Million EUR | 0.0% |
| 2019 Q2 | 16.32 Million EUR | 2042.19% |
| 2019 FY | 29.37 Million EUR | -28.84% |
| 2019 Q4 | 16.3 Million EUR | 0.0% |
| 2019 Q1 | -840.75 Thousand EUR | -104.32% |
| 2018 Q2 | 21.3 Million EUR | 16335.43% |
| 2018 Q1 | -131.25 Thousand EUR | -100.3% |
| 2018 FY | 41.28 Million EUR | 39.34% |
| 2018 Q4 | 19.47 Million EUR | 0.0% |
| 2017 Q2 | 16.66 Million EUR | 5497.25% |
| 2017 FY | 29.62 Million EUR | -13.06% |
| 2017 Q4 | 43.54 Million EUR | 0.0% |
| 2017 Q1 | -308.75 Thousand EUR | -101.94% |
| 2016 Q4 | 15.89 Million EUR | 0.0% |
| 2016 FY | 34.07 Million EUR | 14.84% |
| 2016 Q2 | 17.48 Million EUR | 2694.36% |
| 2016 Q1 | -674 Thousand EUR | -104.85% |
| 2015 Q4 | 13.88 Million EUR | 25118.02% |
| 2015 FY | 29.67 Million EUR | 48.99% |
| 2015 Q3 | -55.5 Thousand EUR | -100.36% |
| 2015 Q2 | 15.48 Million EUR | 27997.3% |
| 2015 Q1 | -55.5 Thousand EUR | -100.54% |
| 2014 Q1 | -240.75 Thousand EUR | -102.13% |
| 2014 FY | 19.91 Million EUR | 79.79% |
| 2014 Q4 | 10.3 Million EUR | 4382.04% |
| 2014 Q3 | -240.75 Thousand EUR | -103.74% |
| 2014 Q2 | 6.43 Million EUR | 2770.82% |
| 2013 Q3 | 1.48 Million EUR | -47.51% |
| 2013 Q4 | 11.28 Million EUR | 660.84% |
| 2013 FY | 11.07 Million EUR | 313.53% |
| 2013 Q1 | 1.48 Million EUR | 0.0% |
| 2013 Q2 | 2.82 Million EUR | 90.5% |
| 2012 Q2 | -2.69 Million EUR | 0.0% |
| 2012 FY | -5.18 Million EUR | -256.67% |
| 2012 Q1 | -2.69 Million EUR | 0.0% |
| 2012 Q3 | -2.69 Million EUR | 0.0% |
| 2012 Q4 | 1.48 Million EUR | 155.02% |
| 2011 Q4 | -2.69 Million EUR | -379.69% |
| 2011 Q1 | -561.96 Thousand EUR | 0.0% |
| 2011 Q2 | -561.96 Thousand EUR | 0.0% |
| 2011 Q3 | -561.96 Thousand EUR | 0.0% |
| 2011 FY | 3.31 Million EUR | 0.0% |
| 2010 Q4 | -561.96 Thousand EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Nicox S.A. | -11.5 Million EUR | 173.807% |
| European Medical Solutions | 13.64 Million EUR | 37.789% |
| FERMENTALG | 12.34 Million EUR | 31.222% |
| argenx SE | 1.34 Billion EUR | 99.368% |
| BioSenic S.A. | 7.58 Million EUR | -11.961% |
| Hyloris Pharmaceuticals SA | 17.98 Million EUR | 52.799% |
| Onward Medical N.V. | 20.64 Million EUR | 58.876% |
| Oxurion NV | 12.21 Million EUR | 30.49% |
| PHAXIAM Therapeutics S.A. | 24.98 Million EUR | 66.021% |
| Financière de Tubize SA | 114.38 Thousand EUR | -7322.042% |
| UCB SA | 2.94 Billion EUR | 99.711% |